|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KDM6B mRNA expression is downregulated in poorly differentiated high-risk neuroblastomas and upregulated in differentiated tumors, and high KDM6B expression is prognostic for better survival in neuroblastoma patients.
|
30631055 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The association between the levels of P16INK4A, lysine demethylase 6B (KDM6B) and the methylation status of histone 3 lysine 27 (H3K27) in these cell lines and the human USC tumor sample was also demonstrated.
|
30896884 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed high-throughput drug screening of epigenetic-targeted therapies across a large and diverse tumor cell line panel and uncovered the hypersensitivity of neuroblastoma cells to GSK-J4, a small-molecule dual inhibitor of lysine 27 of histone 3 (H3K27) demethylases ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), and histone demethylase Jumonji D3 (JMJD3).
|
29769286 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stratified analyses revealed that upregulated expression of JMJD3 was significantly associated with poorly differentiated tumor nuclear grade (p= 0.005) and advanced clinical stage (p= 0.043) in the bladder cancer group, while downregulated expression of JMJD3 was significantly associated with advanced clinical stage (p= 0.045) and poorly differentiated tumor nuclear grade (p= 0.011) in the RCC group.
|
27983522 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
H3K27 Demethylase JMJD3 Employs the NF-κB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
|
26729791 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, treatment with siRNA to JMJD3 reduced tumor volume concordant with increased apoptosis in either subtype.
|
27102442 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This glioma study brings together actions of a normal epigenetic mechanism (JMJD3 activity) with dysfunctional activation of senescence-related processes, including secretion of SASP proinflammatory cytokines and stem cell tropism toward tumors.
|
25652587 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the validation set, significantly lower levels of KAT2B (P = 0.008), HDAC11 (P = 0.009), KMT1C (P = 0.05), KDM4B (P = 0.003), KDM6B (P = 0.04), and BMI-1 (P = 0.001) transcripts were found in tumors with M3/class 2.
|
25593028 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that knockdown of KDM6B in PDAC cells promoted tumor sphere formation and increased peritoneal dissemination and liver metastasis in vivo.
|
24947179 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p16(INK4A) tumor suppressor is a critical KDM6B downstream transcriptional target and its expression is critical for cell survival.
|
24046371 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis.
|
22020331 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
|
23236496 |
2012 |